|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RERG |
Gene summary for RERG |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RERG | Gene ID | 85004 |
| Gene name | RAS like estrogen regulated growth inhibitor | |
| Gene Alias | RERG | |
| Cytomap | 12p12.3 | |
| Gene Type | protein-coding | GO ID | GO:0001558 | UniProtAcc | Q96A58 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 85004 | RERG | ATC13 | Human | Thyroid | ATC | 1.30e-64 | 1.29e+00 | 0.34 |
| 85004 | RERG | ATC5 | Human | Thyroid | ATC | 2.79e-67 | 1.34e+00 | 0.34 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001604927 | Thyroid | ATC | cell growth | 241/6293 | 482/18723 | 4.27e-14 | 2.35e-12 | 241 |
| GO:000726524 | Thyroid | ATC | Ras protein signal transduction | 172/6293 | 337/18723 | 2.25e-11 | 7.96e-10 | 172 |
| GO:000155826 | Thyroid | ATC | regulation of cell growth | 201/6293 | 414/18723 | 1.57e-10 | 4.76e-09 | 201 |
| GO:004592622 | Thyroid | ATC | negative regulation of growth | 115/6293 | 249/18723 | 2.34e-05 | 2.06e-04 | 115 |
| GO:003030813 | Thyroid | ATC | negative regulation of cell growth | 90/6293 | 188/18723 | 3.35e-05 | 2.78e-04 | 90 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RERG | SNV | Missense_Mutation | c.193N>A | p.Glu65Lys | p.E65K | Q96A58 | protein_coding | deleterious(0.01) | probably_damaging(0.953) | TCGA-LP-A7HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| RERG | SNV | Missense_Mutation | c.563A>G | p.Gln188Arg | p.Q188R | Q96A58 | protein_coding | tolerated(0.27) | benign(0.015) | TCGA-AA-3672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| RERG | SNV | Missense_Mutation | rs746482571 | c.536N>A | p.Arg179Gln | p.R179Q | Q96A58 | protein_coding | deleterious(0.01) | possibly_damaging(0.848) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| RERG | SNV | Missense_Mutation | novel | c.422N>T | p.Ala141Val | p.A141V | Q96A58 | protein_coding | deleterious(0.03) | benign(0.144) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| RERG | SNV | Missense_Mutation | c.530C>T | p.Thr177Met | p.T177M | Q96A58 | protein_coding | deleterious(0.05) | benign(0.048) | TCGA-G4-6628-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| RERG | deletion | Frame_Shift_Del | c.163delN | p.Ser55ProfsTer5 | p.S55Pfs*5 | Q96A58 | protein_coding | TCGA-AD-6895-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |||
| RERG | SNV | Missense_Mutation | rs763229225 | c.506G>A | p.Arg169His | p.R169H | Q96A58 | protein_coding | deleterious(0) | probably_damaging(0.976) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| RERG | SNV | Missense_Mutation | c.49G>A | p.Val17Met | p.V17M | Q96A58 | protein_coding | deleterious(0) | possibly_damaging(0.882) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| RERG | SNV | Missense_Mutation | rs199912990 | c.538N>T | p.Arg180Cys | p.R180C | Q96A58 | protein_coding | deleterious(0) | probably_damaging(0.962) | TCGA-AX-A06J-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | SD |
| RERG | SNV | Missense_Mutation | novel | c.470N>T | p.Thr157Ile | p.T157I | Q96A58 | protein_coding | tolerated(0.19) | benign(0.017) | TCGA-AX-A0J1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |